Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of June 2022, specifically dated June 9, 2022. The registrant is a foreign private issuer based in Petach-Tikva, Israel, and files annual reports on Form 20-F.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a disclosure of a corporate event rather than a financial statement.
Material Changes
The primary material event disclosed is the issuance of a press release on June 9, 2022, announcing the publication of clinical study data for the company's compounds, Piclidenoson and Namodenoson, in a scientific journal.
Guidance, Outlook, and Risks
The filing incorporates by reference a press release (Exhibit 99.1) regarding clinical data publication. No specific financial guidance, management outlook, risk factors, or contingencies are detailed within the body of this specific Form 6-K text.
Key Facts for Investor Verification
- Verify the full text of the press release attached as Exhibit 99.1 for details on the clinical study data.
- Confirm the specific scientific journal where the data for Piclidenoson and Namodenoson was published.
- Review the company's most recent Form 20-F for comprehensive financial metrics, as this filing contains none.